Cresemba is an antifungal medicine used to treat adults and children aged 1 year and older with invasive aspergillosis or mucormycosis (infections caused by fungi). For mucormycosis, Cresemba is used when another medicine, amphotericin B, is not suitable. Invasive aspergillosis and mucormycosis are rare, and Cresemba was designated an ‘orphan medicine’ (a medicine used in rare diseases). Further information on the orphan designations can be found on the EMA website ( [mucormycosis](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1276): 4 June 2014; [invasive aspergillosis](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1284): 4 July 2014). Cresemba contains the active substance isavuconazole.
Therapeutic Indication
### Therapeutic indication Powder for concentrate for solution for infusion: Cresemba is indicated in patients from 1 year of age and older for the treatment of - invasive aspergillosis - mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1) Consideration should be given to official guidance on the appropriate use of antifungal agents. Hard capsules: Cresemba hard capsules are indicated in adults and in paediatric patients from 6 years of age for the treatment of - invasive aspergillosis - mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1) Consideration should be given to official guidance on the appropriate use of antifungal agents. Cresemba 40 mg hard capsules are intended to be used for paediatric patients.
Therapeutic Area (MeSH)
ATC Code
J02AC05
ATC Item
isavuconazole
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| isavuconazole | N/A | Isavuconazonium |
EMA Name
Cresemba
Medicine Name
Cresemba
Aliases
N/A
